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Abstract
Background: Pneumococcal infections are major causes of child mortality and morbidity worldwide and antibiotic
resistance of Streptococcus pneumoniae is a major concern, especially in Asian countries. The present study was
designed to evaluate the reactogenicity and safety of the 10-valent pneumococcal non-typeable Haemophilus
influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the licensed diphtheria, tetanus,
acellular pertussis, hepatitis B virus, inactivated poliovirus and H. influenzae type b vaccine (DTPa-HBV-IPV/Hib) in a
3-dose primary vaccination course in Vietnamese infants.
Methods: This phase III, open, randomised study was conducted in one centre in Ho Chi Minh City between
February and July 2011. Healthy infants (N=300) were randomised (2:1) to receive either PHiD-CV co-administered
with DTPa-HBV-IPV/Hib (PHiD-CV group) or DTPa-HBV-IPV/Hib alone (Control group) at 2, 3, and 4 months of age.
Results: Within 31 days post-vaccination, 8.2% of overall doses in the PHiD-CV group and 3.0% of overall doses in
the Control group were followed by at least one solicited and/or unsolicited, local and/or general adverse event of
grade 3 intensity. Pain at injection site was the most common grade 3 solicited symptom, which was reported
following 6.5% and 1.0% of overall doses in the PHiD-CV and Control groups, respectively. Within 4 days post-
vaccination, the most common solicited local and general symptoms reported with any intensity were pain (48.9%
and 31.0% of doses in the PHiD-CV and Control groups) and irritability (58.0% and 40.4% of doses in the PHiD-CV
and Control groups). Within 31 days post-vaccination, the incidence of unsolicited symptoms was comparable in
both groups (following 12.3% and 14.8% of doses in the PHiD-CV and Control groups, respectively). Throughout the
study, 13 serious adverse events (SAEs) were reported in 9 infants in the PHiD-CV group and 11 SAEs in 6 infants in
the Control group. None of them were fatal or considered causally related to vaccination.
Conclusions: PHiD-CV had a clinically acceptable safety profile when co-administered with DTPa-HBV-IPV/Hib in
Vietnamese infants. The reactogenicity of PHiD-CV was comparable to that observed in other South-East Asian
populations.
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Background
Pneumococcal infections are a major cause of child mor-
tality and morbidity worldwide, especially in developing
countries [1]. In Vietnam, the incidence of invasive
pneumococcal disease was estimated to be at least 48.7
cases per 100,000 children younger than 5 years of age
in a previous study conducted in Khanh Hoa Province in
2005–2006 [2]. The most common pneumococcal sero-
types detected in children younger than 5 years of age in
Hanoi between 1997 and 1999 were serotypes 23F, 19F,
6B, and 14 (ordered according to frequency) [3]. In a
prospective study conducted in 2008–2009, similar serotype
distributions have been observed in Vietnamese patients
from all age groups, in whom the major pneumococcal
serotypes were 19F, 23F, 14, 11, and 6B [4]. In Vietnam,
high and increasing rates of antibiotic resistance among
pneumococcal isolates have been observed, which may po-
tentially be explained by the frequent and inappropriate use
of antibiotics in that country and by the spread of multi-
resistant strains [3-7].
Although routine vaccination of infants and toddlers
with effective pneumococcal conjugate vaccines has been
shown to be the best strategy to prevent invasive dis-
eases caused by Streptococcus pneumoniae in children
younger than 5 years of age, there is no pneumococcal
conjugate vaccine currently available in Vietnam [8-10].
A 10-valent pneumococcal non-typeable Haemophilus
influenzae (NTHi) protein D conjugate vaccine (Synflorix™,
GlaxoSmithKline, Rixensart, Belgium; hereafter referred as
PHiD-CV), which offers protection against pneumococcal
serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, has
been licensed in more than 110 countries across the world
since 2008. Previous clinical trials conducted in various
countries have shown that PHiD-CV co-administered with
routinely used childhood vaccines in infants or young chil-
dren was immunogenic and had a clinically acceptable
safety profile [11-23].
In Vietnam, the safety and reactogenicity profile of a
new vaccine needs to be evaluated in the local target
population before the vaccine can be registered in the
country. Therefore, the present study was designed to
evaluate the safety and reactogenicity of PHiD-CV when
co-administered with the licensed diphtheria, tetanus,
acellular pertussis, hepatitis B virus, inactivated polio-
virus, and H. influenzae type b vaccine (Infanrix hexa™,
GlaxoSmithKline, Rixensart, Belgium; hereafter referred
as DTPa-HBV-IPV/Hib) in a 3-dose primary vaccination
course in Vietnamese infants.
Methods
Study objectives
The primary objective of this study was to evaluate the
safety and reactogenicity of 3-dose primary vaccination
with PHiD-CV co-administered with DTPa-HBV-IPV/Hib
in terms of grade 3 solicited (local or general) adverse
events (AEs) reported within 4 days post-vaccination and
grade 3 unsolicited AEs reported within 31 days post-
vaccination in Vietnamese infants.
The secondary objectives included the evaluation of the
safety and reactogenicity in terms of local and general
solicited AEs reported within 4 days after each vaccination,
unsolicited AEs within 31 days after each vaccination, and
serious adverse events (SAEs) throughout the study.
Study vaccines
PHiD-CV (Synflorix™, GlaxoSmithKline, Rixensart,
Belgium) contained 1 μg of each capsular polysaccharide
of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F
and 3 μg of serotype 4 capsular polysaccharide conju-
gated individually to NTHi protein D; 3 μg of serotype
18C capsular polysaccharide conjugated to tetanus tox-
oid; and 3 μg of serotype 19F capsular polysaccharide
conjugated to diphtheria toxoid. PHiD-CV was adminis-
tered intramuscularly in the anterolateral region of the
right thigh of the infants in the PHiD-CV group.
The DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™,
GlaxoSmithKline, Rixensart, Belgium) contained ≥30 IU
of diphtheria toxoid, ≥40 IU of tetanus toxoid, 25 μg of
pertussis toxoid, 25 μg of filamentous haemagglutinin,
8 μg pertactin, 10 μg of recombinant hepatitis B surface
antigen, 40 D antigen units of poliovirus type 1, 8 D
antigen units of poliovirus type 2, 32 D antigen units of
poliovirus type 3, and 10 μg of Hib polysaccharide
polyribosylribitol phosphate conjugated to 20–40 μg of
tetanus toxoid. The DTPa-HBV-IPV/Hib vaccine was
administered intramuscularly in the anterolateral region
of the left thigh of the infants in both groups.
Study design and participants
This phase III, open-label, randomised study was con-
ducted between February 2011 and July 2011 in one of
the largest tertiary hospitals of Ho Chi Minh City (the
Children Hospital No. 2 [Nhi Dong 2]) in cooperation
with the Clinical Research Unit of the Pasteur Institute
of Ho Chi Minh City.
Study participants were recruited from the hospital
vaccination clinic, where parents bring their infants for
routine childhood immunisations. Eligible participants
were healthy infants aged between and including 6–12
weeks (42–90 days) at the time of the first vaccination.
Infants were excluded from participation if they had re-
ceived previous vaccination against diphtheria, tetanus,
pertussis, Hib and/or S. pneumoniae. Written and
signed informed consent was obtained before enrolment
from the parents or legally acceptable representatives
(LARs) of the infants. After the parents or LARs
granted informed consent, a study physician assessed
the eligibility of the infants by obtaining information on
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their medical history and performing physical examina-
tions. A transportation allowance was provided to par-
ticipants for the fourth visit, and no other financial
compensation was provided. The study was conducted
in accordance with the Good Clinical Practice guidelines
and the Declaration of Helsinki, and the protocol and
associated documents were reviewed and approved by
national and local ethics committees (Institutional Review
Boards of Nhi Dong 2 Hospital and Pasteur Institute,
Service of Health and People’s Committee, Ho Chi
Minh City, and Independent Ethics Committee of
the Vietnamese Ministry of Health). This study has
been registered at www.clinicaltrials.gov NCT01153841. A
summary of the protocol is available at http://www.gsk-
clinicalstudyregister.com (GlaxoSmithKline study IDs
113151).
Randomisation
Study participants were randomised (2:1 treatment allo-
cation ratio) to receive 3-dose primary vaccination at
2, 3, and 4 months of age with either PHiD-CV co-
administered with DPTa-HBV-IPV/Hib (PHiD-CV group)
or DTPa-HBV-IPV/Hib administered alone (Control
group). Infants in the PHiD-CV group received 2 injec-
tions at each vaccination visit while those in the Control
group had only 1 injection per visit. The intervals between
consecutive doses were to range from 28 to 42 days.
Treatment allocation was performed at the investigator
site using a central internet randomisation system. A
randomisation blocking scheme (block size of 3) was
used to ensure a balanced distribution of the infants in
each group.
Reactogenicity and safety assessment
Local (pain, redness, and swelling at injection site) and
general (drowsiness, fever, irritability, and loss of appe-
tite) symptoms were actively solicited and recorded dur-
ing a 4-day period after each vaccination using diary
cards that were completed by the infants’ parents or
LARs. Unsolicited AEs were recorded during a period of
31 days after each vaccination. The intensity of each
solicited symptom was graded on a scale from 1 to 3.
Grade 3 symptoms were defined as follows: pain at the
injection site if the limb was spontaneously painful or if
the infant cried when it was moved, redness and swelling
at the injection site if the diameter was >30 mm, fever if
axillary temperature was >39.5°C, loss of appetite if the
infant did not eat at all, and irritability if the infant cried
and could not be comforted or if it prevented normal ac-
tivity. All other AEs were considered of grade 3 intensity
if they prevented normal activity. The prevalence of con-
comitant antipyretic (prophylactic or therapeutic) medi-
cation during the 4-day post-vaccination period was
also recorded. SAEs were recorded throughout the en-
tire study. A SAE was defined as any untoward medical
occurrence that resulted in death, was life-threatening,
required hospitalisation or prolongation of existing hos-
pitalisation, or resulted in disability or incapacity. All
solicited local reactions were considered causally related
to vaccination as defined in the protocol. Using their
Enrolled and randomised (N = 300)
PHiD-CV group (N = 199) Control group (N = 101)
Total vaccinated cohort (N = 199) Total  vaccinated cohort (N = 99)
6 infants withdrawn:
1 - serious adverse event
2 - protocol violation
1 - consent withdrawal 
2 - lost to follow-up
Completed the study (N = 193) Completed the study (N = 99)
2 infants did not receive the study vaccine 
Figure 1 Trial profile. Footnote: PHiD-CV group= infants vaccinated with PHiD-CV co-administered with DTPa-HBV-IPV/Hib at 2, 3, and 4 months
of age. Control group= infants vaccinated with DTPa-HBV-IPV/Hib at 2, 3, and 4 months of age. N= number of infants.
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clinical judgment, the investigators assessed the causality
of all other AEs.
Statistical analyses
The safety and reactogenicity analyses were performed
on the total vaccinated cohort (TVC), which included all
infants with at least one vaccine dose administration. In
this study, 300 infants were planned to be enrolled (200
in the PHiD-CV group and 100 in the Control group).
Incidences of solicited local and general symptoms dur-
ing the 4-day post-vaccination period and unsolicited
AEs during the 31-day post-vaccination period were cal-
culated with exact 95% confidence interval (CI) after
each vaccine dose and overall, according to the type of
symptom, intensity, and relationship to vaccination. The
overall incidence of AEs was calculated as the propor-
tion of vaccine doses followed by at least one type of
symptom. The prevalence of concomitant antipyretic
medication during the 4-day post-vaccination period was
also computed with exact 95% CI. SAEs and withdrawals
due to SAEs were described in detail. This study was
a descriptive study and although non-overlapping 95%
CIs might indicate potential differences between study
groups, these comparisons should be interpreted with
caution considering that there were no adjustments for
multiple comparisons of the various endpoints. The statis-
tical analyses were performed using the SDD (i.e. Statistical
Analysis System [SAS] Drug and Development) web portal
version 3.5 and SAS version 9.2.
Results
Study participants
Between February 2011 and April 2011, 300 infants were
enrolled in this study; 199 in the PHiD-CV group and
101 in the Control group (Figure 1). Of these, 199 in-
fants in the PHiD-CV group and 99 infants in the Con-
trol group received at least one vaccine dose and were
included in the TVC. The demographic characteristics of
the infants included in the TVC were comparable in the
2 groups at the time of the first vaccination, although
the proportion of boys seemed lower in the PHiD-CV
group than in the Control group (53.3% versus 62.6%)
(Table 1). All the infants were younger than 90 days
of age at the time of the first dose administration. In
the PHiD-CV group, the pre-specified interval between
doses was exceeded by 2 infants between the first and
the second dose (maximum 49 days) and by one infant
between the second and the third dose (45 days). These
3 infants were included in the TVC.
Primary objective
Within 31 days post-vaccination, 8.2% of overall doses in
the PHiD-CV group and 3.0% of overall doses in the
Control group were followed by at least one type of
grade 3 AE (solicited and/or unsolicited, local and/or
general) (Table 2).
Within 4 days post-vaccination, pain at the injection
site was the most frequently reported grade 3 solicited
local symptom, which was reported following 6.5% and
1.0% of overall doses in the PHiD-CV and Control groups,
respectively. In the PHiD-CV group, the most common
grade 3 solicited general symptom was irritability, which
was reported following 1.9% of overall doses and was con-
sidered causally related to vaccination following 1.7% of
overall doses. In the Control group, irritability and fever
were the only grade 3 solicited general symptoms and
each symptom was reported following one dose (0.3% of






Age (weeks) Mean ± SD 8.8 ± 1.24 8.7 ± 1.11
Range 6–12 6–12
Gender Female n (%) 93 (46.7) 37 (37.4)
Male n (%) 106 (53.3) 62 (62.6)
Race Asian – South East
Asian heritage n (%)
199 (100) 99 (100)
PHiD-CV group= infants vaccinated with PHiD-CV co-administered with DTPa-
HBV-IPV/Hib at 2, 3, and 4 months of age; Control group= infants vaccinated
with DTPa-HBV-IPV/Hib at 2, 3, and 4 months of age; N= number of infants;
n= (%) number (percentage) of infants with the specified characteristic;
SD= standard deviation; Range= Minimum-Maximum values.
Table 2 Incidence of overall per dose grade 3 solicited
symptoms reported within 4 days post-vaccination and
of grade 3 unsolicited symptoms reported within 31 days





Grade 3 Symptom n % [95% CI] n % [95% CI]
Any symptom 48 8.2 [6.1, 10.8] 9 3.0 [1.4, 5.7]
Local symptom 43 7.4 [5.4, 9.8] 6 2.0 [0.7, 4.3]
Pain 38 6.5 [4.7, 8.8] 3 1.0 [0.2, 2.9]
Redness 5 0.9 [0.3, 2.0] 1 0.3 [0.0, 1.9]
Swelling 7 1.2 [0.5, 2.5] 2 0.7 [0.1, 2.4]
General symptom 13 2.2 [1.2, 3.8] 3 1.0 [0.2, 2.9]
Drowsiness 3 0.5 [0.1, 1.5] 0 0.0 [0.0, 1.2]
Fever 0 0.0 [0.0, 0.6] 1 0.3 [0.0, 1.9]
Irritability 11 1.9 [0.9, 3.4] 1 0.3 [0.0, 1.9]
Loss of appetite 0 0.0 [0.0, 0.6] 0 0.0 [0.0, 1.2]
Unsolicited symptom 2 0.3 [0.0, 1.2] 1 0.3 [0.0, 1.9]
PHiD-CV group= infants vaccinated with PHiD-CV co-administered with DTPa-
HBV-IPV/Hib at 2, 3, and 4 months of age; Control group= infants vaccinated
with DTPa-HBV-IPV/Hib at 2, 3, and 4 months of age; N= number of doses;
*= number of administered doses for unsolicited symptom; n= number of
reported symptoms; %= percentage of doses followed by the specified
symptom with grade 3 intensity; 95% CI= 95% confidence interval.
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overall doses). Grade 3 fever that was considered causally
related to vaccination was reported following one dose
(0.3% of overall doses) in the Control group.
In both groups, grade 3 unsolicited symptoms were
uncommon; they were reported following 2/585 doses
(constipation and fungal infection; 0.3% of overall doses)
in the PHiD-CV group and following 1/297 doses (fungal
infection; 0.3% of overall doses) in the Control group.
None of the grade 3 unsolicited symptoms were consid-
ered causally related to vaccination.
Secondary objectives
Solicited symptoms
During the 4-day post-vaccination period, the most fre-
quently reported solicited local symptom following each
vaccine dose was pain at the injection site (Figure 2).
Figure 2 Percentages of doses followed by pain (A), redness (B), and swelling (C) at the specified injection site of any intensity and
grade 3 intensity reported during the 4-day post-vaccination period (total vaccinated cohort). Footnote: PHiD-CV group= infants
vaccinated with PHiD-CV co-administered with DTPa-HBV-IPV/Hib at 2, 3, and 4 months of age. Control group= infants vaccinated with DTPa-
HBV-IPV/Hib at 2, 3, and 4 months of age. Grade 3 symptoms: pain if the infant was crying when the limb was moved or if the limb was
spontaneously painful and redness or swelling if the diameter was >30 mm. Error bars indicate 95% confidence intervals.
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Overall, pain was reported following 48.9% and 31.0% of
doses, redness following 23.2% and 14.8% of doses, and
swelling following 20.6% and 11.4% of doses in the
PHiD-CV and Control groups, respectively (Figure 3).
In the PHiD-CV group, the incidence of each solicited
local symptom was comparable at both injection sites
(PHiD-CV and DTPa-HBV-IPV/Hib) after each vaccine
dose (Figure 2) and the overall per dose frequencies of
symptoms at each injection site were within similar
ranges (data not shown).
In both groups, the most frequently reported solicited
general symptom following each vaccine dose was irri-
tability (Figure 4). The overall per dose incidence of
solicited general symptoms seemed to be higher in the
PHiD-CV group compared with the Control group (irri-
tability: 58.0% versus 40.4%; fever: 54.5% versus 21.5%;
loss of appetite: 46.3% versus 29.0%; and drowsiness:
26.2% versus 11.4%) (Figure 3).
Antipyretic medication use within 4 days post-
vaccination was infrequent in both groups and was
reported following 3.2% (95% CI: 2.0–5.0) of overall
doses in the PHiD-CV group and following 1.0% (95%
CI: 0.2–2.9) of overall doses in the Control group (data
not shown).
Unsolicited symptoms
Within 31 days post-vaccination, unsolicited AEs were
reported following 12.3% (95% CI: 9.8–15.2) and 14.8%
(95% CI: 11.0–19.4) of doses in the PHiD-CV and
Control groups, respectively (data not shown). The most
frequently reported unsolicited symptoms were upper re-
spiratory tract infection (following 3.8% [95% CI: 2.4–5.6]
and 3.0% [95% CI: 1.4–5.7] of doses in the PHiD-CV and
Control groups, respectively) and bronchiolitis (following
1.9% [95% CI: 0.9–3.3] and 3.4% [95% CI: 1.6–6.1] of doses
in the PHiD-CV and Control groups, respectively).
Unsolicited symptoms considered causally related to vac-
cination were reported following one dose in the PHiD-CV
group (rash) and following one dose in the Control group
(vomiting). Unsolicited symptoms with medically attended
visit were reported following 9.4% (95% CI: 7.2–12.1) of
doses in the PHiD-CV group and 8.4% (95% CI: 5.5–12.2)
of doses in the Control group.
Serious adverse events
Throughout the entire study period, 13 SAEs were
reported in 9 infants in the PHiD-CV group: convulsion,
diarrhoea, bronchiolitis (n=2 for each SAE), autoimmune
thrombocytopenia, upper respiratory tract infection,
gastro-oesophageal reflux disease, hydronephrosis, fungal
infection, Kawasaki’s disease, and coagulopathy (n=1 for
each SAE). In the Control group, 11 SAEs were reported
in 6 infants: bronchiolitis (n=3), diarrhoea, fungal infec-
tion (n=2 for each SAE), urinary tract infection, gastro-
oesophageal reflux disease, oral candidiasis, and viral
Figure 3 Incidence of overall per dose solicited local (pain, redness, and swelling) and general (drowsiness, fever, irritability, and loss
of appetite) symptoms of any intensity and grade 3 intensity reported during the 4-day post-vaccination period (total vaccinated
cohort). Footnote: PHiD-CV group= infants vaccinated with PHiD-CV co-administered with DTPa-HBV-IPV/Hib at 2, 3, and 4 months of age.
Control group= infants vaccinated with DTPa-HBV-IPV/Hib at 2, 3, and 4 months of age. Grade 3 symptoms: pain if the infant was crying when
the limb was moved or if the limb was spontaneously painful, redness or swelling if the diameter was >30 mm, drowsiness if it prevented normal
activity, fever if axillary temperature was >39.5°C, irritability if the infant was crying and could not be comforted or if it prevented normal activity,
and loss of appetite if the infant did not eat at all. Error bars indicate 95% confidence intervals.
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infection (n=1 for each SAE). None of these SAEs were
fatal or considered to be causally related to vaccination.
Discussion
In Vietnam, the reactogenicity and safety of a new vac-
cine need to be evaluated in the local target population
before the vaccine can be registered in the country. In
the present study, the reactogenicity and safety profile
of PHiD-CV co-administered with DTPa-HBV-IPV/Hib in
Vietnamese infants seemed in line with that observed in
previous studies, in which PHiD-CV was co-administered
with routine childhood vaccines [13,21-23].
Within the 31-day post-vaccination period, 8.2% of over-
all doses were followed by at least one grade 3 symptom
(solicited and/or unsolicited, local and/or general) in the
infants who received PHiD-CV co-administered with
DTPa-HBV-IPV/Hib, while this was 3.0% of overall doses
in the infants who received DTPa-HBV-IPV/Hib alone.
This difference was mainly due to the higher proportion
of doses followed by grade 3 pain during the 4-day post-
vaccination period in the infants who received both vac-
cines co-administered compared with those who received
DTPa-HBV-IPV/Hib alone (6.5% [95% CI: 4.7, 8.8] versus
1.0% [95% CI: 0.2, 2.9] of overall doses). This difference
in incidence of pain was not unexpected and could be
explained by the fact that the infants of the PHiD-CV
group had 2 injections at each vaccination visit while
those in the Control group had only 1 injection per visit.
The most frequently reported grade 3 solicited general
symptom in the infants who received PHiD-CV co-
administered with DTPa-HBV-IPV/Hib was irritability,
which was reported following 1.9% (95% CI: 0.9, 3.4) of
doses. The use of antipyretic medication was low in both
groups and grade 3 fever was only reported in one infant
vaccinated with DTPa-HBV-IPV/Hib alone.
Figure 4 Percentages of doses followed by drowsiness (A), fever (B), irritability (C), and loss of appetite (D) of any intensity and grade
3 intensity reported during the 4-day post-vaccination period (total vaccinated cohort). Footnote: PHiD-CV group= infants vaccinated with
PHiD-CV co-administered with DTPa-HBV-IPV/Hib at 2, 3, and 4 months of age. Control group= infants vaccinated with DTPa-HBV-IPV/Hib at 2, 3,
and 4 months of age. Grade 3 symptoms: drowsiness if it prevented normal activity, fever if axillary temperature was >39.5°C, irritability if the
infant was crying and could not be comforted or if it prevented normal activity, and loss of appetite if the infant did not eat at all. Error bars
indicate 95% confidence intervals.
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The incidence and nature of the grade 3 solicited symp-
toms reported in this study were in line with those reported
in a previous study assessing the co-administration of
PHiD-CV and DTPa-HBV-IPV/Hib in Taiwanese infant. In
that study, the most frequently reported grade 3 solicited
local and general symptoms were pain (following 4.2% of
doses [95% CI: 2.8, 6.0]) and irritability (following 6.3%
of doses [95% CI: 4.6, 8.4]) [21]. In another study, in which
PHiD-CV was co-administered with a monovalent vaccine
against Hib in Korean infants, grade 3 solicited symptoms
were reported following no more than 2.6% of doses,
which seems slightly lower than the reporting rates
observed in the present study [22]. When compared
to co-administration of PHiD-CV and DTPa-based
or Hib vaccines, the incidence of grade 3 symptoms
seemed higher when PHiD-CV was co-administered with
whole cell pertussis-based combination vaccines, as ob-
served in 2 Asian studies, in which the incidence of
grade 3 pain reached 9.4% (95% CI: 6.4, 13.3) and
27.7% (95% CI: 24.4, 31.1) of doses and grade 3 irritabil-
ity, 2.9% (95% CI: 1.9, 4.2) and 8.3% (95% CI: 6.4, 10.6) of
doses in infants in the Philippines and India, respectively
[13,23]. This observation was expected since whole cell
pertussis-based vaccines are known to induce more
adverse events than DTPa-based vaccines [24].
In the present study, pain was the most frequently
reported solicited local symptom with any intensity, which
was reported following 48.9% (95% CI: 44.8, 53.0) of PHiD-
CV doses co-administered with DTPa-HBV-IPV/Hib. In
contrast, redness was the most common solicited local
symptom in previous Asian studies conducted in Taiwan
and Korea, in which PHiD-CV was also co-administered
with DTPa-based vaccines [21,22]. In the previous studies
conducted in India and the Philippines, pain was also the
most common solicited local symptom following co-
administration of PHiD-CV and whole cell pertussis-based
vaccines (following 71.0% of doses [95% CI: 67.6, 74.4] and
67.2% of doses [95% CI: 64.0, 70.3]) [13,23]. The incidence
of solicited local symptoms was comparable at both
injections sites in the infants who received PHiD-CV
co-administered with DTPa-HBV-IPV/Hib, but solicited
local and general symptoms seemed more frequently
reported in infants who received PHiD-CV in addition
to DTPa-HBV-IPV/Hib than in those who received
DTPa-HBV-IPV/Hib alone.
The percentage of doses followed by at least one
unsolicited adverse event within the 31-day post-
vaccination period was comparable in both groups and
the incidences of grade 3 unsolicited symptoms were
low. Unsolicited symptoms causally related to vaccin-
ation were only reported in one child in each group.
Throughout the study, 15 infants (9/199 infants in the
PHiD-CV group and 6/99 infants in the Control group)
reported at least one SAE. None of these SAEs were
fatal or considered by the investigator to be causally
related to vaccination.
This study had a very high compliance rate since 97.0%
of the infants who received PHiD-CV co-administered with
DTPa-HBV-IPV/Hib and all the infants vaccinated with
DTPa-HBV-IPV/Hib alone received the 3 vaccine doses.
However, potential limitation of the study included its
non-blinded (open) design, due to the different number of
injections in both groups. The open design might have
induced a bias in the reactogenicity and safety profile
towards increased reporting of AEs in infants in the
PHiD-CV group since their parents or LARs and the inves-
tigators were aware that they had received a new vaccine
in addition to the antigens received by the infants in the
Control group. Another limitation of this study was the fact
that there were no confirmatory analyses with regards to
the reactogenicity and safety objectives. Due to above men-
tioned limitations, the study results should be interpreted
with caution.
Conclusions
This study showed that 3-dose primary vaccination with
PHiD-CV co-administered with DTPa-HBV-IPV/Hib at
2, 3, and 4 months of age had a clinically acceptable
reactogenicity and safety profile in Vietnamese infants,
which was in line with that observed in other South-East
Asian populations [13,22]. These results lend support for
the introduction of PHiD-CV in routine paediatric vac-
cination programmes in Vietnam, a country where no
pneumococcal conjugate vaccines are currently available
and where young children could have substantial benefit
from immunisation against pneumococcal disease.
Synflorix and Infanrix hexa are registered trademarks
of the GlaxoSmithKline group of companies.
Abbreviations
AE: Adverse event; CI: Confidence interval; DTPa-HBV-IPV/Hib: Diphtheria,
tetanus, acellular pertussis, hepatitis B virus, inactivated poliovirus, and
Haemophilus influenzae type b vaccine; Hib: Haemophilus influenzae type b;
LAR: Legally acceptable representative; NTHi: Non-typeable Haemophilus
influenzae; PHiD-CV: 10-valent pneumococcal non-typeable Haemophilus
influenzae protein D conjugate vaccine; SAE: Serious adverse event;
TVC: Total vaccinated cohort.
Competing interests
TNH was the Principal Investigator for this study conducted in Vietnam.
GlaxoSmithKline Biologicals SA was the funding source and was involved in
all stages of the study conduct and analysis. NTT, HMT and HLV declare no
conflict of interest. PLTB received funding for the study from
GlaxoSmithKline Biologicals SA. FS is employed by GlaxoSmithKline group of
companies. TWY, DB, and AH are employed by GlaxoSmithKline group of
companies and have stock/stock options ownership.
Authors’ contributions
TNH, HMT, NTT, HLV, AH, and DB were involved in the planning and design
of the reported study; TNH, TWY, AH, and DB, in the review and finalisation
of the reported study; AH, in the overall follow-up of the study; TNH, in the
choice and recruitment of investigators and in the coordination of the study;
PLTB, HMT, and HLV, in the provision of subjects; TNH, HMT, HLV, PLTB, NTT,
and TWY, in the collection of the data; TNH, HMT, NTT, TWY, AH, and DB, in
Huu et al. BMC Infectious Diseases 2013, 13:95 Page 8 of 10
http://www.biomedcentral.com/1471-2334/13/95
the interpretation of the results; HMT, in supervising the analysis; HLV and
PLTB, in the acquisition of funding; TNH and PLTB, in the supervision of the
study group; and FAS, in statistical analysis and data management. All
authors reviewed the different drafts of the manuscript and approved the
final version.
Acknowledgements
The authors are indebted to the study participants and their parents,
clinicians, nurses, and laboratory technicians at the study site. The authors
would also like to thank Nancy Francois for her statistical input and review of
the final draft, Katrien Tartagila, for clinical operation, Syed Yasin, for scientific
writing, and Vinod Ramesh, for clinical data management. We are also
grateful to all teams of GlaxoSmithKline Vaccines for their contribution to
this study, especially Nguyen Thuy An and Tran My Phuc for local clinical
operations, Doan Thi Ngoc Khuyen, for local clinical operations as well as
manuscript coordination locally, and members of the study team at the
hospital, such as Pham Mai Dang, Huynh Tan Khoa, Le Van Loi and Duong
Thi Hong Thuy, for recruitment of participants and study conduct. Finally we
thank Claire Verbelen (XPE Pharma & Science for GlaxoSmithKline Vaccines)
who provided medical writing services and Aneta Skwarek-Maruszewska (XPE
Pharma & Science for GlaxoSmithKline Vaccines) for editorial assistance and
manuscript coordination.
Funding
GlaxoSmithKline Biologicals SA was the funding source and was involved in
all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA
also funded all costs associated with the development and the publishing of
the present manuscript.
Author details
1Pasteur Institute Ho Chi Minh City, 167 Pasteur Street District, 3 Ho Chi Minh
City, Vietnam. 2Children’s Hospital 2, Ho Chi Minh City, Vietnam.
3GlaxoSmithKline Vaccines, 20 Avenue Fleming, 1300, Wavre, Belgium.
4GlaxoSmithKline Pharmaceuticals, 5 Embassy Links, SRT Road, Bangalore 560
052, India.
Received: 17 July 2012 Accepted: 19 February 2013
Published: 21 February 2013
References
1. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P,
Campbell H, Walker CF, Cibulskis R, Eisele T, Liu L, Mathers C: Global,
regional, and national causes of child mortality in 2008: a systematic
analysis. Lancet 2010, 375:1969–1987.
2. Anh DD, Kilgore PE, Slack MP, Nyambat B, le Tho H, Yoshida LM, Nguyen
HA, Nguyen CD, Chong CY, Nguyen D, Ariyoshi K, Clemens JD, Jodar L:
Surveillance of pneumococcal-associated disease among hospitalized
children in Khanh Hoa Province, Vietnam. Clin Infect Dis 2009,
48(Suppl 2):S57–S64.
3. Bogaert D, Ha NT, Sluijter M, Lemmens N, De Groot R, Hermans PW:
Molecular epidemiology of pneumococcal carriage among children with
upper respiratory tract infections in Hanoi, Vietnam. J Clin Microbiol 2002,
40:3903–3908.
4. Kim SH, Song JH, Chung DR, Thamlikikul V, Yang Y, Wang H, Lu M, So TM,
Hsueh PR, Yasin RM, Carlos CC, Pham HV, Lalitha MK, Shimono N, Perera J,
Shibl AM, Baek JY, Kang CI, Ko KS, Peck KR: Changing trend of
antimicrobial resistance and serotypes in Streptococcus pneumoniae in
Asian countries: an ANSORP study. Antimicrob Agents Chemother 2012,
56:1418–1426.
5. Hoa NQ, Trung NV, Larsson M, Eriksson B, Phuc HD, Chuc NT, Lundborg CS:
Decreased Streptococcus pneumoniae susceptibility to oral antibiotics
among children in rural Vietnam: a community study. BMC Infect Dis
2010, 10:85.
6. Parry CM, Diep TS, Wain J, Hoa NT, Gainsborough M, Nga D, Davies C, Phu
NH, Hien TT, White NJ, Farrar JJ: Nasal carriage in Vietnamese children of
Streptococcus pneumoniae resistant to multiple antimicrobial agents.
Antimicrob Agents Chemother 2000, 44:484–488.
7. Parry CM, Duong NM, Zhou J, Mai NTH, Diep TS, Thinh LQ, Wain J, Chau
NVV, Griffiths D, Day NP, White NJ, Hien TT, Spratt BG, Farrar JJ: Emergence
in Vietnam of Streptococcus pneumoniae resistant to multiple
antimicrobial agents as a result of dissemination of the multiresistant
Spain(23F)-1 clone. Antimicrob Agents Chemother 2002, 46:3512–3517.
8. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM,
Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W,
Austrian R: Efficacy, safety and immunogenicity of heptavalent pneumococcal
conjugate vaccine in children. Pediatr Infect Dis J 2000, 19:187–195.
9. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Kayhty
H, Karma P, Kohberger R, Siber G, Makela PH: Efficacy of a pneumococcal
conjugate vaccine against acute otitis media. N Engl J Med 2001,
344:403–409.
10. World Health Organisation: Pneumococcal conjugate vaccine for childhood
immunization - WHO position paper. Wkly Epidemiol Rec 2007, 82:93–104.
11. Bermal N, Szenborn L, Edison A, Hernandez M, Pejcz J, Majda-Stanislwska E,
Gatchalian S, Fanic A, Dieussaert I, Schuerman L: Safety and
immunogenicity of a booster dose of the 10-valent pneumococcal
nontypeable Haemophilus influenzae protein D conjugate vaccine
coadministered with DTPw-HBV/Hib and poliovirus vaccines.
Pediatr Infect Dis J 2011, 30:69–72.
12. Bermal N, Szenborn L, Chrobot A, Alberto E, Lommel P, Gatchalian S,
Dieussaert I, Schuerman L: The 10-valent pneumococcal non-typeable
Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment
of immunogenicity. Pediatr Infect Dis J 2009, 28(Suppl 4):S89–S96.
13. Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, Borys D,
Cleerbout J, Lommel P, Schuerman L: Safety and reactogenicity of the
10-valent pneumococcal non-typeable Haemophilus influenzae protein D
conjugate vaccine (PHiD-CV) when coadministered with routine
childhood vaccines. Pediatr Infect Dis J 2009, 28(Suppl 4):S109–S118.
14. Lagos RE, Munoz AE, Levine MM, Lepetic A, François N, Yarzabal JP,
Schuerman L: Safety and immunogenicity of the 10-valent pneumococcal
nontypeable Haemophilus influenzae protein D conjugate vaccine
(PHiD-CV) in Chilean children. Hum Vaccin 2011, 7:511–522.
15. Omenaca F, Merino JM, Tejedor JC, Constantopoulos A, Papaevangelou V,
Kafetzis D, Tsirka A, Athanassiadou F, Anagnostakou M, François N, Borys D,
Schuerman L: Immunization of preterm infants with 10-valent
pneumococcal conjugate vaccine. Pediatrics 2011, 128:e290–e298.
16. Silfverdal SA, Hogh B, Bergsaker MR, Skerlikova H, Lommel P, Borys D,
Schuerman L: Immunogenicity of a 2-dose priming and booster vaccination
with the 10-valent pneumococcal nontypeable Haemophilus influenzae
protein D conjugate vaccine. Pediatr Infect Dis J 2009, 28:e276–e282.
17. Vesikari T, Karvonen A, Korhonen T, Karppa T, Sadeharju K, Fanic A,
Dieussaert I, Schuerman L: Immunogenicity of 10-valent pneumococcal
nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when
administered as catch-up vaccination to children 7 months to 5 years of
age. Pediatr Infect Dis J 2011, 30:e130–e141.
18. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène J-P, Lommel
P, Dieussaert I, Schuerman L: Immunogenicity of the 10-valent
pneumococcal non-typeable Haemophilus influenzae protein D
conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Pediatr Infect Dis J 2009, 28(Suppl 4):S66–S76.
19. Ruiz-Palacios GM, Guerrero ML, Hernandez-Delgado L, Lavalle-Villalobos A,
Casas-Munoz A, Cervantes-Apolinar Y, Moreira M, Schuerman L:
Immunogenicity, reactogenicity and safety of the 10-valent
pneumococcal nontypeable Haemophilus influenzae protein D conjugate
vaccine (PHiD-CV) in Mexican infants. Hum Vaccin 2011, 7:1137–1145.
20. Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L,
Dieussaert I, Schuerman L: Immunogenicity of the 10-valent
pneumococcal non-typeable Haemophilus influenzae protein D
conjugate vaccine (PHiD-CV) when coadministered with different
Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J
2009, 28(Suppl 4):S77–S88.
21. Lin T-Y, Lu C-Y, Chang L-Y, Chiu C-H, Huang Y-C, Bock HL, Tang H, François
N, Moreira M, Schuerman L, Huang L-M: Immunogenicity and safety of 10-
valent pneumococcal non-typeable Haemophilus influenzae protein D-
conjugate vaccine (PHiD-CV) co-administered with routine childhood
vaccines in Taiwan. J Formos Med Assoc, in press.
22. Kim CH, Kim JS, Cha SH, Kim KN, Kim JD, Lee KY, Kim HM, Kim JH, Hyuk S,
Hong JY, Park SE, Kim YK, Kim NH, Fanic A, Borys D, Ruiz-Guinazu J, Moreire
M: Response to primary and booster vaccination with 10-valent
pneumococcal nontypeable Haemophilus influenzae protein D conjugate
vaccine in Korean infants. Pediatr Infect Dis J 2011, 30:e235–243.
Huu et al. BMC Infectious Diseases 2013, 13:95 Page 9 of 10
http://www.biomedcentral.com/1471-2334/13/95
23. Lalwani S, Chatterjee S, Chhatwal J, Verghese VP, Mehta S, Shafi F, Borys D,
Moreira M, Schuerman L: Immunogenicity, safety, and reactogenicity of
the 10-valent pneumococcal non-typeable Haemophilus influenzae
protein D conjugate vaccine (PHiD-CV) when co-administered with the
DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized,
controlled study. Human Vaccin Immunother 2012, 8:612–622.
24. Jefferson T, Rudin M, DiPietrantonj C: Systematic review of the effects of
pertussis vaccines in children. Vaccine 2003, 21:2003–2014.
doi:10.1186/1471-2334-13-95
Cite this article as: Huu et al.: Safety and reactogenicity of primary
vaccination with the 10-valent pneumococcal non-typeable
Haemophilus influenzae protein D conjugate vaccine in Vietnamese
infants: a randomised, controlled trial. BMC Infectious Diseases 2013 13:95.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Huu et al. BMC Infectious Diseases 2013, 13:95 Page 10 of 10
http://www.biomedcentral.com/1471-2334/13/95
